Answers go deeper than the script: questioning keeps surfacing new concrete detail behind a positive development · broad
The model's full reasoning — Q1 2023 call → NOThe task is to evaluate two gates independently using only the provided earnings call transcript. **Gate 1 — Original Signal:** The question asks: Is there a POSITIVE, CURRENT development in the company's business for which the Q&A discussion produces MORE CONCRETE OPERATING DETAIL than the prepared remarks contained? The answers must keep adding new, specific, present-tense substance. Let me analyze the transcript. The call covers several topics: 1. VTAMA sales and payer coverage 2. Brepocitinib (with new Crohn's data, lupus data upcoming, dermatomyositis program) 3. Immunovant (IMVT-1402) upcoming data 4. RVT-3101 (TL1A) program 5. Vant (discovery efforts) The main positive current developments: - VTAMA commercial launch progress (scripts, prescribers, revenue, payer coverage) - Brepocitinib data (Crohn's positive data, but they're not progressing it there; lupus data upcoming) - IMVT-1402 upcoming data (not yet read out) Let me look at the Q&A for each: **VTAMA:** - Prepared remarks: 11,500 prescribers, 200,000 scripts, 130 million lives covered, $16.7M net revenue, gross-to-net 26%, etc. - Q&A: Doug Tsao asks about co-pay card changes and accelerating prescriptions from low prescribers. - Matt's answers: "we have no immediate plans to change the co-pay card... set up in a way... to work well for us as people migrate from uncovered to covered." He talks about DTC campaign ramping up, patients not going to doctor often, payer coverage perception issue. - Is this additive? He mentions DTC campaign ramping up (which was mentioned in prepared remarks: "our now live DTC campaigns"). He talks about the co-pay card design (somewhat new detail). He talks about the coverage perception issue. But is this "more concrete operating detail"? It's somewhat general — about doctor behavior, time, compounding effects. Not really new specific numbers or facts. **Brepocitinib:** - Prepared remarks: extensive detail on the program, Crohn's data, lupus upcoming, DM program, HS, NIU. - Q&A: Brian Chen asks about confidence in SLE vs Ducros (Sotyktu), baseline characteristics. Matt answers about the bar being mid-teens, study design. Mayukh adds about Sotyktu's inverse dose response being due to imbalances. - David Risinger asks about decision not to pursue indications (Crohn's) and Sotyktu's inverse dose response.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| FTAI | Fortress Transportation and Infrastructu | Q2 2024 | 2024-07-24 | A |
| FYBR | Frontier Communications Parent, Inc. | Q1 2024 | 2024-05-03 | B |
| TOL | Toll Brothers, Inc. | Q1 2024 | 2024-02-21 | A |
| GDDY | GoDaddy Inc. | Q4 2023 | 2024-02-13 | A |
| ZWS | Zurn Elkay Water Solutions Corporation | Q4 2023 | 2024-02-07 | B |
| TMUS | T-Mobile US, Inc. | Q4 2023 | 2024-01-25 | B |
| VCEL | Vericel Corporation | Q3 2023 | 2023-11-08 | A |
| WEAV | Weave Communications, Inc. | Q3 2023 | 2023-11-01 | B+ |
| MAC | The Macerich Company | Q3 2023 | 2023-10-31 | D |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| MNSO | MINISO Group Holding Limited | Q4 2023 | 2023-08-22 | A |
| PFGC | Performance Food Group Company | Q4 2023 | 2023-08-16 | B+ |
| SURG | SurgePays, Inc. | Q2 2023 | 2023-08-12 | D |
| EVLV | Evolv Technologies Holdings, Inc. | Q2 2023 | 2023-08-10 | B+ |
| TREX | Trex Company, Inc. | Q2 2023 | 2023-07-31 | B+ |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| NOW | ServiceNow, Inc. | Q2 2023 | 2023-07-26 | A |
| UTHR | United Therapeutics Corporation | Q1 2023 | 2023-05-03 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| MGM | MGM Resorts International | Q1 2023 | 2023-05-01 | A |
| EDU | New Oriental Education & Technology Grou | Q3 2023 | 2023-04-19 | B |
| PAYX | Paychex, Inc. | Q3 2023 | 2023-03-29 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C |
| CUTR | Cutera, Inc. | Q3 2022 | 2022-11-05 | C |
| INMD | InMode Ltd. | Q3 2022 | 2022-10-27 | A |
| SHW | The Sherwin-Williams Company | Q2 2022 | 2022-07-27 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| ABNB | Airbnb, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| APLE | Apple Hospitality REIT, Inc. | Q4 2021 | 2022-02-23 | A |
| DV | DoubleVerify Holdings, Inc. | Q3 2021 | 2021-11-11 | B |
| ENV | Envestnet, Inc. | Q3 2021 | 2021-11-08 | B+ |
| AMH | American Homes 4 Rent | Q3 2021 | 2021-11-05 | B+ |
| BIGC | BigCommerce Holdings, Inc. | Q3 2021 | 2021-11-04 | B+ |
| SPSC | SPS Commerce, Inc. | Q3 2021 | 2021-10-28 | A |
| INBK | First Internet Bancorp | Q3 2021 | 2021-10-21 | B+ |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| SNY | Sanofi | Q3 2018 | 2018-10-31 | B+ |
| GAIA | Gaia, Inc. | Q2 2018 | 2018-08-06 | A |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| VRTX | Vertex Pharmaceuticals Incorporated | Q1 2018 | 2018-04-26 | C+ |
| SNDR | Schneider National, Inc. | Q1 2018 | 2018-04-26 | A |
| ROKU | Roku, Inc. | Q4 2017 | 2018-02-21 | A |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| INTU | Intuit Inc. | Q3 2017 | 2017-05-23 | A |
| SAH | Sonic Automotive, Inc. | Q1 2017 | 2017-04-26 | C |
| FIVN | Five9, Inc. | Q4 2016 | 2017-02-17 | A |
| SQ | Square's | Q2 2016 | 2016-08-04 | A |
| SEM | Select Medical Holdings Corporation | Q1 2016 | 2016-05-06 | C+ |
| PLNT | Planet Fitness, Inc. | Q4 2015 | 2016-03-03 | A |
| BECN | Beacon Roofing Supply, Inc. | Q1 2016 | 2016-02-05 | B |
APLE · Q4 2021 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES The transcript shows a clear positive current development in the company's hotel portfolio recovery, particularly around Q1 2022 demand trends and operational metrics. In prepared remarks, Justin Knight and Liz Perkins highlight overall RevPAR improvement, leisure strength, and business travel recovery, but without granular February specifics.
MKC · Q2 2018 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. YES NO (Gate 2 fails because the Frank’s/French’s growth is repeatedly tied to specific large retailers, national accounts, and one major customer whose shelf-reset decisions and promotional activity are named or implied as key drivers; the transcript never establishes a broad, granular base of many independent counterparties whose small decisions are widening adoption.
GAIA · Q2 2018 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES The transcript shows a positive current development in organic subscriber growth and the member referral program. Prepared remarks note organic contributions over 40% and reduced marketing spend. Q&A provides additive details: specific referral mechanics (7-day free watch), ambassador program vs.